Log in

NASDAQ:SPPISpectrum Pharmaceuticals Stock Price, Forecast & News

$3.68
-0.25 (-6.36 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.63
Now: $3.68
$4.04
50-Day Range
$2.99
MA: $3.37
$3.93
52-Week Range
$1.74
Now: $3.68
$10.57
Volume4.11 million shs
Average Volume2.08 million shs
Market Capitalization$428.60 million
P/E RatioN/A
Dividend YieldN/A
Beta2.02
Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkin's lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB, a pan-HER inhibitor for non-small cell lung cancer tumors; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly to hospitals and cancer centers in the United States; and through distributors in Europe. It has a strategic partnership with Servier Canada, Inc.; licensing and development agreement with Cell Therapeutics, Inc.; license agreements with Merck & Cie AG, Medac Pharma, Inc., Sloan-Kettering Institute for Cancer Research, SRI International, Southern Research Institute, Medac Pharma, Inc., Cydex Pharmaceuticals, Inc., and Mundipharma International Corporation Limited; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreements with Hanmi Pharmaceutical Co. Ltd and The University of Texas MD Anderson Cancer Center. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.
Read More
Spectrum Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.54 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SPPI
CUSIP84763A10
Phone702-835-6300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$109.33 million
Book Value$1.69 per share

Profitability

Net Income$-112,690,000.00

Miscellaneous

Employees235
Market Cap$428.60 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$3.68
-0.25 (-6.36 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

How has Spectrum Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Spectrum Pharmaceuticals' stock was trading at $2.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SPPI stock has increased by 54.0% and is now trading at $3.68.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Spectrum Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Spectrum Pharmaceuticals
.

When is Spectrum Pharmaceuticals' next earnings date?

Spectrum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Spectrum Pharmaceuticals
.

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced its quarterly earnings data on Monday, August, 10th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.33) by $0.05.
View Spectrum Pharmaceuticals' earnings history
.

What price target have analysts set for SPPI?

4 analysts have issued 12 month price objectives for Spectrum Pharmaceuticals' stock. Their forecasts range from $7.00 to $13.00. On average, they expect Spectrum Pharmaceuticals' stock price to reach $9.33 in the next year. This suggests a possible upside of 153.6% from the stock's current price.
View analysts' price targets for Spectrum Pharmaceuticals
.

Has Spectrum Pharmaceuticals been receiving favorable news coverage?

News articles about SPPI stock have trended negative recently, according to InfoTrie. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Spectrum Pharmaceuticals earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future.
View the latest news about Spectrum Pharmaceuticals
.

Are investors shorting Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals saw a decrease in short interest in the month of February. As of February 15th, there was short interest totaling 6,770,000 shares, a decrease of 34.0% from the January 31st total of 10,250,000 shares. Based on an average daily volume of 2,640,000 shares, the short-interest ratio is currently 2.6 days. Approximately 6.9% of the shares of the company are sold short.
View Spectrum Pharmaceuticals' Short Interest
.

Who are some of Spectrum Pharmaceuticals' key competitors?

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Exelixis (EXEL), Verastem (VSTM), Zynerba Pharmaceuticals (ZYNE), Bausch Health Companies (BHC), TG Therapeutics (TGTX), Clovis Oncology (CLVS), Amicus Therapeutics (FOLD), Opko Health (OPK) and Progenics Pharmaceuticals (PGNX).

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the following people:
  • Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 61)
  • Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 51)
  • Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 43)
  • Mr. Keith M. McGahan J.D., L.L.M., Sr. VP, Chief Legal Officer & Corp. Sec. (Age 43)
  • Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Macquarie Group Ltd. (2.77%), Alethea Capital Management LLC (0.97%), Principal Financial Group Inc. (0.77%), Swiss National Bank (0.22%), Russell Investments Group Ltd. (0.15%) and Sargent Investment Group LLC (0.13%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Dolatrai Vyas, Francois Lebel, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Stuart Mitchell Krassner, Thomas J Riga and William Ashton.
View institutional ownership trends for Spectrum Pharmaceuticals
.

Which institutional investors are selling Spectrum Pharmaceuticals stock?

SPPI stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Sargent Investment Group LLC, Amalgamated Bank, Texas Permanent School Fund, and SG Americas Securities LLC. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Francois Lebel, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Thomas J Riga, and William Ashton.
View insider buying and selling activity for Spectrum Pharmaceuticals
.

Which institutional investors are buying Spectrum Pharmaceuticals stock?

SPPI stock was bought by a variety of institutional investors in the last quarter, including Alethea Capital Management LLC, Macquarie Group Ltd., Swiss National Bank, Rafferty Asset Management LLC, Russell Investments Group Ltd., New York State Common Retirement Fund, Magnus Financial Group LLC, and XTX Markets LLC.
View insider buying and selling activity for Spectrum Pharmaceuticals
.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $3.68.

How big of a company is Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals has a market capitalization of $428.60 million and generates $109.33 million in revenue each year. The biotechnology company earns $-112,690,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Spectrum Pharmaceuticals employs 235 workers across the globe.

What is Spectrum Pharmaceuticals' official website?

The official website for Spectrum Pharmaceuticals is www.sppirx.com.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.